Strategic Equity Capital plc · LSE:SEC
Strategic Equity Capital — Q2 2019 Earnings Presentation
34 slides from Strategic Equity Capital's earnings presentation, 2019
Slide 1: Strategic Equity Capital plc Q2 Update 2019
STRATEGIC EQUITY CAPITAL PLC Q2 Update 2019
Slide 2: Risk considerations
Risk considerations Risk Factors for Strategic Equity Capital plc (the Company”) – The general risk factors set out under the heading “D.1.Key Risks” of the Prospectus apply to the Company. In addition, potential investors should note the following factors: • There can be no guarantee that the inves
Slide 3: Notice to recipients
Notice to recipients This document is given to the recipient on condition that the recipient accepts that it is not a client of GVQ Investment Management Limited (“GVQIM”) and that hence, none of the client protections applicable to GVQIM’s clients are in fact in force or available, and GVQIM is not
Slide 4: Contents
Contents Q2 Update 2019 • Executive Summary 6 • Performance 7 • Detailed portfolio analysis 8 Outlook 15 Conclusion 21 Appendix 23 4
Slide 5: Q2 Update 2019
Q2 UPDATE 2019
Slide 6: Executive summary
Executive summary • SEC (the “Trust”) had another strong quarter; net assets per share increased by 4.5%¹, this was above the return of the FTSE Small Cap ex IT index (the “index”) which delivered a total return of 0.9%. SEC’s share price increased by 10.4%. The discount to NAV at the end of the per
Slide 7: Fund performance
Fund performance Annualised 20 14.9 15.3 15 12.4 10.6 10 9.2 7.7 5.4 4.5 5 2.9 2.4 0.9 0 -5 -10 -8.6 3 months 1 year 7 Feb 2017* 3 years 5 years 7 years SEC NAV Total Return FTSE Small Cap x IT Total Return Average 8.5% 7.5% 8.4% 9.4% 9.5% 9.8% Net Cash Strong NAV return in the short and longer term
Slide 8: Q2 Attribution analysis
Q2 Attribution analysis Positive attribution bps GVQIM Comment Positive trading update with upgrades to full year expectations. Strong new CFO hire, who, along with the Ergomed 232 Executive Chairman purchase >£850k of shares EMIS 83 In line AGM statement Positive AGM statement and completion of sep
Slide 9: Changes to top 10 holdings
Changes to top 10 holdings Top 10 Q1 2019 Top 10 Q2 2019 Company % of portfolio Company % of portfolio IFG Group 11.8 Equiniti Group 12.2 Equiniti Group 10.8 Tyman Group 6.6 Wilmington 7.2 Clinigen Group 6.5 Tribal Group 6.7 Tribal Group 6.5 4imprint Group 6.5 Wilmington 6.4 Medica 6.3 4imprint Grou
Slide 10: Medica Group – a recap of the company
Medica Group – a recap of the company 35% 25 6 30% 4 20 2 25% Operating margin 0 15 Sales £m 20% £m -2 15% 10 -4 10% -6 5 5% -8 0% 0 -10 H117 H217 H118 H218 H117 H217 H118 H218 Sales Operating margin Operating cash flow Net debt/cash No. of radiologists 267 306 339 362 • Since listing, the company h
Slide 11: Medica Group – Investment Thesis
Medica Group – Investment Thesis Medica Group – the UK’s leading teleradiology provider • Average sales growth rate of c.17% • High growth, predictable revenue since IPO. All organic streams and low capital intensity are coveted by financial buyers • This growth is supported by multiple long term st
Slide 12: Top 10 holdings
Top 10 holdings1 GVQIM GVQIM Net debt/ Company Sector Funds % of CF yield2 Investment thesis EBITDA NTM3 company NTM3 Growth through demonstrable cross-sell and margin Equiniti Group Support Services c. 6% 11.2% 2.1x improvement through automation and offshoring and integration of WFSS acquisition;
Slide 13: Highly concentrated and unconstrained portfolio
Highly concentrated and unconstrained portfolio Sector exposure by value Value by market cap band 1 Healthcare 22.6% 1 <£50m 1.1% 9 8 12 8 7 7 1 2 Support services 19.3% 2 £50m - £100m 0.0% 3 £100m - £200m 6 3 Financials 16.7% 3 31.1% 4 Industrials 11.8% 4 £200m - £300m 13.7% 6 5 5 5 £300m - £500m T
Slide 14: Portfolio valuation
Portfolio valuation1 SEC SEC FTSE UK Small Cap ex weighted average median investment trusts Number of securities 20 20 157 Market cap (£m) 455 260 282 Consensus EV/EBITDA FY1 9.6x 9.8x 6.5x Consensus price earnings FY1 15.0x 13.9x 15.1x Consensus FY1 earnings growth 11.4% 10.6% 7.0% Consensus divide
Slide 15: Outlook
OUTLOOK
Slide 16: Global private equity dry powder levels at record highs
Global private equity dry powder levels at record highs Private Equity Dry Powder by Fund Type, 2009 - 2018 Global public-to-private deal value $1,200bn $450 bn 200 $1,000bn $400 bn $350 bn 150 $800bn Deal count Deal value $300 bn $600bn $250 bn 100 $200 bn $400bn $150 bn $100 bn 50 $200bn $50 bn $0
Slide 17: Global private equity financing is generationally low
Global private equity financing is generationally low Investor views on funds types presenting the best opportunities1 HY bond yields over time (Bloomberg global high yield bond index) 2 Buyout - Small to mid-market 54% 25% Growth 29% Secondaries 23% 20% Buyout - Large to mega 18% VC - Early stage 1
Slide 18: Bearishness around UK equities, marginal moderation in H1
Bearishness around UK equities, marginal moderation in H1 Price and trailing DPS of UK MSCI index over time 240 200 160 120 80 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Price Trailing DPS Highly negative view of UK equities reflected in >£10bn of net outflo
Slide 19: Bear market checklist
Bear market checklist Start of Proper Bear Markets Mar-00 Oct-07 Now Global Equity Valuations Trailing PE 33 17 18 Fwd PE 24 14 15 DY 1.3 2.1 2.5 CAPE 48 30 24 Global Equity Risk Premium 1.0% 3.3% 4.6% US Yield Curve (10Y minus 2Y) -0.5 0.0 0.2 Sentiment Global Analyst Bullishness (std dev) 1.7 1.0
Slide 20: Earnings growth, cashflow and M&A to drive returns
Earnings growth, cashflow and M&A to drive returns SEC portfolio • Double digit aggregate earnings • Private Equity ‘dry powder’ at record growth for the portfolio levels. Any resolution to UK uncertainty could see acquirers • Portfolio growth exceeds the market, return despite portfolio’s much lowe
Slide 21: Conclusion
CONCLUSION
Slide 22: Conclusion
Conclusion • SEC had another strong quarter with net assets per share increasing by 4.5%¹ • SEC’s share price increased by 10.4%, with the discount ending the period at 13.8% • The FTSE Small Cap ex IT index delivered a total return of 0.9% • Markets are volatile with fragile economic indicators. Th
Slide 23: Appendix
APPENDIX
Slide 24: Equiniti – a reminder of the thesis
Equiniti – a reminder of the thesis Equiniti – a market leading specialist technology and business process outsourcer • Customers include 70% of FTSE 100 • High value on the strength of cash flows companies and 70% of newly listed and structural growth drivers to both PE companies and trade: • Oppor
Slide 25: Approach for IFG Group
Approach for IFG Group 2.00 Company announces proposed sale of Saunderson • On 25 March, a recommended cash offer was made by Epiris House and potential Elysian Fuels liability Funds at 193p, a 46% premium to the closing share price, a trailing 1.90 PE valuation of 21.4x. SEC owns 9.9% of the shares
Slide 26: Portfolio investment themes
Portfolio investment themes DIVERSIFIED DIGITAL HEALTH REGULATION AND PENSIONS INFRASTRUCTURE PHARMA COMPLIANCE AND AND SAVINGS BUILDING Demographic and Digital maturity agenda; Increasing compliance Increase in complexity US single family population changes replacement of legacy and regulatory burd
Slide 27: How we identify value in potential investments
How we identify value in potential investments Main focus of most Main focus of most PUBLIC EQUITY INVESTORS PRIVATE EQUITY INVESTORS All investments undergo All investments are valued in-house, prospective using an in house cash-flow and historic leveraged buy-out model modelling Focus on recent re
Slide 28: Asset quality
There are strict criteria for inclusion in our funds Speculative Fair valued GARP1 Under valued Recovery Turnaround Distress growth A A Investment Asset quality Asset quality focus B Avoid Avoid B C Avoid C GVQIM’s research process aims to identify high quality coveted assets with attractive cash fl
Slide 29: How we identify coveted assets
How we identify coveted assets We look for characteristics which GVQIM believes potential acquirers value highly Qualitative Quantitative • Niche market leaders • High and/or improving ROCE • Orderly end markets, with some growth • Strong cash conversion • Sustainable business model/franchise/unique
Slide 30: Our Black List screens out companies with fundamental business risks
Our Black List screens out companies with fundamental business risks Operational • Excessive reliance on a single product, customer, supplier or distributor • The primary driver of profitability cannot be influenced by management (e.g. resources) • Inherently low margins • Structurally declining mar
Slide 31: Research Committee ensures consistency of approach
Research Committee ensures consistency of approach Preliminary Investment Final Investment Monitoring Idea generation Investment Memorandum Recommendation & review Recommendation Materials • Watch list • Company description • Company meeting • Counterparty analysis • Progress against • M&A transacti
Slide 32: Long term track record
Long term track record Cumulative rebased total returns1 300 CAGR¹ 280 SEC NAV 18.9% 260 240 220 200 180 160 FTSE Small Cap ex IT 12.2% 140 120 100 80 60 40 Jun 09 Jun 10 Jun 11 Jun 12 Jun 13 Jun 14 Jun 15 Jun 16 Jun 17 Jun 18 Jun 19 Strong cumulative performance since process improvements in June 2
Slide 33: Performance
Performance Calendar Year annual performance YTD 2019 2018 2017 2016 2015 2014 2013 2012 Share Price Total Return 16.6% -17.6% 20.2% -9.0% 14.2% 32.7% 61.5% 25.6% NAV Total Return 13.5% -14.1% 21.7% 6.3% 12.1% 18.1% 46.1% 21.3% FTSE Small Cap ex Investment Trusts Total Return 6.1% -13.8% 15.6% 12.5%
Slide 34: Contact details
Contact details For further information regarding the SEC please contact the GVQ Investment Management marketing team below, or visit the Company’s website: www.strategicequitycapital.com For general enquiries, please contact: GVQ Investment Management Limited 16 Berkeley Street, London, W1J 8DZ Tel
Strategic Equity Capital — Q2 2019 Earnings Presentation on 6ix